[Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
Identifieur interne : 001B22 ( Main/Exploration ); précédent : 001B21; suivant : 001B23[Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
Auteurs : K. Hashigucci ; S. Tamura ; T. Kurata ; H. Kamiya ; T. IshidateSource :
- Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases [ 0387-5911 ] ; 1997.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Entérotoxines, Vaccins antigrippaux.
- analyse : Hétérosides, Triterpènes.
- Administration par voie nasale, Adulte, Adulte d'âge moyen, Entérotoxines, Escherichia coli, Femelle, Grippe humaine, Humains, Mâle, Vaccination.
English descriptors
- KwdEn :
- Administration, Intranasal, Adult, Enterotoxins (administration & dosage), Enterotoxins (chemistry), Escherichia coli, Female, Glycosides (analysis), Humans, Influenza Vaccines (administration & dosage), Influenza, Human (prevention & control), Male, Middle Aged, Triterpenes (analysis), Vaccination.
- MESH :
- chemical , administration & dosage : Enterotoxins, Influenza Vaccines.
- chemical , analysis : Glycosides, Triterpenes.
- chemical , chemistry : Enterotoxins.
- prevention & control : Influenza, Human.
- Administration, Intranasal, Adult, Escherichia coli, Female, Humans, Male, Middle Aged, Vaccination.
Abstract
We conducted a field trial to evaluate the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in preventing or attenuating influenza among volunteers during the winter season of 1994-1995. A trivalent inactivated influenza vaccine, composed of A/Yamagata/32/89 (H1N1), A/Kitakyusyu/159/93 (H2N2) and B/Mie/1/93 influenza virus strains, was administered intranasally together with recombinant LTB containing 1% recombinant LT (LTB*). Vaccination was done twice 4 weeks apart. Salivary secretory IgA and serum HI antibodies were measured before and 8 weeks after the primary vaccination. Thirty-two volunteers were enrolled in this study; 18 volunteers (mean age 37.7 +/- 11.3) were given LTB*-combined vaccine and 14 volunteers (mean age 44.1 +/- 11.3) given placebo. Outbreaks of H3N2 subtype and B type virus were observed during this study period. Six (42.9%) of the 14 volunteers in the placebo group and 3 (16.7%) of the 18 receiving the LTB*-combined vaccine contracted influenza. There was no statistically significant difference between the two groups, because the number of subjects was small. Higher percentage of positive IgA and HI antibody responses among vaccines given vaccine with LTB* were observed as compared with those in the placebo group. Positive IgA antibody response to all vaccine strains were observed in 46.7% (7/15) of the vaccine group. On the other hand, none of the placebo group showed positive IgA antibody response to all vaccine strains. These results suggest that nasal influenza vaccine with LTB* appears to be effective in preventing influenza.
DOI: 10.11150/kansenshogakuzasshi1970.71.153
PubMed: 9077073
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000393
- to stream PubMed, to step Curation: 000393
- to stream PubMed, to step Checkpoint: 000353
- to stream Ncbi, to step Merge: 001342
- to stream Ncbi, to step Curation: 001342
- to stream Ncbi, to step Checkpoint: 001342
- to stream Main, to step Merge: 001B82
- to stream Main, to step Curation: 001B22
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].</title><author><name sortKey="Hashigucci, K" sort="Hashigucci, K" uniqKey="Hashigucci K" first="K" last="Hashigucci">K. Hashigucci</name><affiliation><nlm:affiliation>E.N.T. Department, Kitasato Institute Hospital.</nlm:affiliation><wicri:noCountry code="subField">Kitasato Institute Hospital</wicri:noCountry></affiliation></author><author><name sortKey="Tamura, S" sort="Tamura, S" uniqKey="Tamura S" first="S" last="Tamura">S. Tamura</name></author><author><name sortKey="Kurata, T" sort="Kurata, T" uniqKey="Kurata T" first="T" last="Kurata">T. Kurata</name></author><author><name sortKey="Kamiya, H" sort="Kamiya, H" uniqKey="Kamiya H" first="H" last="Kamiya">H. Kamiya</name></author><author><name sortKey="Ishidate, T" sort="Ishidate, T" uniqKey="Ishidate T" first="T" last="Ishidate">T. Ishidate</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9077073</idno><idno type="pmid">9077073</idno><idno type="doi">10.11150/kansenshogakuzasshi1970.71.153</idno><idno type="wicri:Area/PubMed/Corpus">000393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000393</idno><idno type="wicri:Area/PubMed/Curation">000393</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000393</idno><idno type="wicri:Area/PubMed/Checkpoint">000353</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000353</idno><idno type="wicri:Area/Ncbi/Merge">001342</idno><idno type="wicri:Area/Ncbi/Curation">001342</idno><idno type="wicri:Area/Ncbi/Checkpoint">001342</idno><idno type="wicri:doubleKey">0387-5911:1997:Hashigucci K:efficacy:of:nasal</idno><idno type="wicri:Area/Main/Merge">001B82</idno><idno type="wicri:Area/Main/Curation">001B22</idno><idno type="wicri:Area/Main/Exploration">001B22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].</title><author><name sortKey="Hashigucci, K" sort="Hashigucci, K" uniqKey="Hashigucci K" first="K" last="Hashigucci">K. Hashigucci</name><affiliation><nlm:affiliation>E.N.T. Department, Kitasato Institute Hospital.</nlm:affiliation><wicri:noCountry code="subField">Kitasato Institute Hospital</wicri:noCountry></affiliation></author><author><name sortKey="Tamura, S" sort="Tamura, S" uniqKey="Tamura S" first="S" last="Tamura">S. Tamura</name></author><author><name sortKey="Kurata, T" sort="Kurata, T" uniqKey="Kurata T" first="T" last="Kurata">T. Kurata</name></author><author><name sortKey="Kamiya, H" sort="Kamiya, H" uniqKey="Kamiya H" first="H" last="Kamiya">H. Kamiya</name></author><author><name sortKey="Ishidate, T" sort="Ishidate, T" uniqKey="Ishidate T" first="T" last="Ishidate">T. Ishidate</name></author></analytic><series><title level="j">Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases</title><idno type="ISSN">0387-5911</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Enterotoxins (administration & dosage)</term><term>Enterotoxins (chemistry)</term><term>Escherichia coli</term><term>Female</term><term>Glycosides (analysis)</term><term>Humans</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Triterpenes (analysis)</term><term>Vaccination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Entérotoxines ()</term><term>Entérotoxines (administration et posologie)</term><term>Escherichia coli</term><term>Femelle</term><term>Grippe humaine ()</term><term>Humains</term><term>Hétérosides (analyse)</term><term>Mâle</term><term>Triterpènes (analyse)</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enterotoxins</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Glycosides</term><term>Triterpenes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Enterotoxins</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Entérotoxines</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Hétérosides</term><term>Triterpènes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>Escherichia coli</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Entérotoxines</term><term>Escherichia coli</term><term>Femelle</term><term>Grippe humaine</term><term>Humains</term><term>Mâle</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We conducted a field trial to evaluate the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in preventing or attenuating influenza among volunteers during the winter season of 1994-1995. A trivalent inactivated influenza vaccine, composed of A/Yamagata/32/89 (H1N1), A/Kitakyusyu/159/93 (H2N2) and B/Mie/1/93 influenza virus strains, was administered intranasally together with recombinant LTB containing 1% recombinant LT (LTB*). Vaccination was done twice 4 weeks apart. Salivary secretory IgA and serum HI antibodies were measured before and 8 weeks after the primary vaccination. Thirty-two volunteers were enrolled in this study; 18 volunteers (mean age 37.7 +/- 11.3) were given LTB*-combined vaccine and 14 volunteers (mean age 44.1 +/- 11.3) given placebo. Outbreaks of H3N2 subtype and B type virus were observed during this study period. Six (42.9%) of the 14 volunteers in the placebo group and 3 (16.7%) of the 18 receiving the LTB*-combined vaccine contracted influenza. There was no statistically significant difference between the two groups, because the number of subjects was small. Higher percentage of positive IgA and HI antibody responses among vaccines given vaccine with LTB* were observed as compared with those in the placebo group. Positive IgA antibody response to all vaccine strains were observed in 46.7% (7/15) of the vaccine group. On the other hand, none of the placebo group showed positive IgA antibody response to all vaccine strains. These results suggest that nasal influenza vaccine with LTB* appears to be effective in preventing influenza.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Hashigucci, K" sort="Hashigucci, K" uniqKey="Hashigucci K" first="K" last="Hashigucci">K. Hashigucci</name><name sortKey="Ishidate, T" sort="Ishidate, T" uniqKey="Ishidate T" first="T" last="Ishidate">T. Ishidate</name><name sortKey="Kamiya, H" sort="Kamiya, H" uniqKey="Kamiya H" first="H" last="Kamiya">H. Kamiya</name><name sortKey="Kurata, T" sort="Kurata, T" uniqKey="Kurata T" first="T" last="Kurata">T. Kurata</name><name sortKey="Tamura, S" sort="Tamura, S" uniqKey="Tamura S" first="S" last="Tamura">S. Tamura</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9077073
|texte= [Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9077073" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |